$ News

Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook

Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition

Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition

Intra-Cellular Therapies, Inc. (ITCI): Among the Best Psychedelic Stocks to Buy in 2025

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

Intra-Cellular: Q4 Earnings Snapshot

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now

Biotech Venture Investors Optimistic, But Uncertainties Persist

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally

Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales

J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns

The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular